These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 623119)

  • 1. Aluminum hydroxide: evaluation of two dosage forms and two dosing schedules in reducing intestinal phosphate absorption.
    Smith DR; Chang BS; Johnson CE
    Am J Hosp Pharm; 1978 Jan; 35(1):58-61. PubMed ID: 623119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of aluminum hydroxide on fluoride and calcium metabolism.
    Spencer H; Kramer L; Osis D; Wiatrowski E
    J Environ Pathol Toxicol Oncol; 1985; 6(1):33-41. PubMed ID: 4067833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative influence of phosphate and aluminium hydroxide on intestinal absorption of phosphorus in the rat].
    Renault H; Rapin J; Bailly G
    Therapie; 1974; 29(3):447-52. PubMed ID: 4439360
    [No Abstract]   [Full Text] [Related]  

  • 6. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.
    Fischer D; Cline K; Plone MA; Dillon M; Burke SK; Blair AT
    Am J Kidney Dis; 2006 Sep; 48(3):437-44. PubMed ID: 16931217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of oral bases on enteral aluminum absorption.
    Walker JA; Sherman RA; Cody RP
    Arch Intern Med; 1990 Oct; 150(10):2037-9. PubMed ID: 2171446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperaluminemia in renal failure: the influence of age and citrate intake.
    Bakir AA; Hryhorczuk DO; Ahmed S; Hessl SM; Levy PS; Spengler R; Dunea G
    Clin Nephrol; 1989 Jan; 31(1):40-4. PubMed ID: 2914409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
    J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of aluminium-hydroxide-containing antacids on the intestinal absorption of iron in patients on long-term dialysis].
    Blumberg A
    Schweiz Med Wochenschr; 1977 Jul; 107(30):1064-6. PubMed ID: 897649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma aluminium levels in patients on maintenance haemodialysis fall when oral aluminium hydroxide is withdrawn.
    Wallace MR; Pybus J
    N Z Med J; 1983 Oct; 96(742):793-5. PubMed ID: 6578451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the possible influence of the absorption of vinpocetine with concomitant application of magnesium-aluminium-hydroxide gel.
    Lohmann A; Grobara P; Dingler E
    Arzneimittelforschung; 1991 Nov; 41(11):1164-7. PubMed ID: 1810262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of muzolimine after oral administration with and without aluminium hydroxide in healthy volunteers.
    Ritter W; Hanisch M; Lücker PW; Venitz F; Hey B; Baykal N
    Z Kardiol; 1985; 74 Suppl 2():149-51. PubMed ID: 4002791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autonomous hyperparathyroidism not associated with increased aluminum absorption.
    Mocan MZ; Mocan H; Fell GS; Junor BJ; Boyce BF
    Isr J Med Sci; 1992 Jan; 28(1):24-6. PubMed ID: 1733894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of aluminum hydroxide on fluoride metabolism.
    Spencer H; Kramer L; Norris C; Wiatrowski E
    Clin Pharmacol Ther; 1980 Oct; 28(4):529-35. PubMed ID: 7408412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the time of administration of calcium acetate on phosphorus binding.
    Schiller LR; Santa Ana CA; Sheikh MS; Emmett M; Fordtran JS
    N Engl J Med; 1989 Apr; 320(17):1110-3. PubMed ID: 2710173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide.
    Sperber AD; Liel Y
    Arch Intern Med; 1992 Jan; 152(1):183-4. PubMed ID: 1728914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.